Male Breast Cancer Completed Phase 1 / 2 Trials for Seviteronel (DB12275)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02580448CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)Treatment